Intravitreal Injection of Bevacizumab (Avastin) to Treat Posterior Capsule Neovascularization
Authors
Abstract:
We report a 64-year-old diabetic woman who developed neovascularization of the posterior capsule 2 years after cataract surgery and intraocular lens implantation. The patient was treated with single injection of 1.25 mg of intravitreal bevacizumab (Avastin) via pars plana. After one week, complete regression of the posterior capsule neovascularization was achieved allowing us to perform Nd: YAG capsulotomy without serious complications. Intravitreal injection of bevacizumab can successfully regress the posterior capsule neovascularization resulting in improving patient's visual acuity.
similar resources
intravitreal injection of bevacizumab (avastin) to treat posterior capsule neovascularization
we report a 64-year-old diabetic woman who developed neovascularization of the posterior capsule 2 years after cataract surgery and intraocular lens implantation. the patient was treated with single injection of 1.25 mg of intravitreal bevacizumab (avastin) via pars plana. after one week, complete regression of the posterior capsule neovascularization was achieved allowing us to perform nd: yag...
full textIntravitreal bevacizumab (Avastin) injection for neovascular glaucoma.
Neovascular glaucoma is a secondary glaucoma with grave prognosis which follows ischemic retinal disorders in the majority of cases. Mediators that induce new vessel formation such as the vascular endothelial growth factor-A seem to play a key role in the pathophysiology of this condition. Herein, we report 2 cases with neovascular glaucoma secondary to ischemic central retinal vein occlusion w...
full text[Intravitreal injection of bevacizumab (Avastin) for retinal angiomatous proliferation].
CLINICAL CASE An 81-year-old man presented with stage 2 retinal angiomatous proliferation (RAP) as identified by fluorescein angiography and optical coherence tomography (OCT), and was shown to have a visual acuity (VA) of 20/40. One week after an intravitreal injection of bevacizumab (1.25 mg) the VA improved to 20/25, and the OCT showed a reduction of both intraretinal edema and pigment epith...
full textPosterior capsule opacification and neovascularization treated with intravitreal bevacizumab and Nd:YAG capsulotomy
We reported a 75-year-old diabetic man, who developed opacification and neovascularization of the posterior capsule after extracapsular cataract extraction and posterior chamber intraocular lens implantation. The patient was treated with two injections of 2.5 mg of intravitreal bevacizumab. The treatment produced an important regression of the posterior capsular new vessels, allowing us to perf...
full textPharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
PURPOSE To describe the pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits. METHODS The right eye of 20 rabbits was injected intravitreally with 1.25 mg/0.05 mL bevacizumab. Both eyes of four rabbits each time were enucleated at days 1, 3, 8, 15, and 29. Bevacizumab concentrations were measured in serum, aqueous humor, and vitreous. RESULTS Maximum vitreous (406.25 μg/mL) an...
full textTesting intravitreal toxicity of bevacizumab (Avastin).
PURPOSE To evaluate the retinal toxicity of varying doses of bevacizumab when injected intravitreally in rabbits. Bevacizumab has been approved by the US Food and Drug Administration for the treatment of metastatic colorectal cancer. MATERIALS AND METHODS Twelve New Zealand albino rabbits were used for this study and divided into four groups. Four concentrations of bevacizumab were prepared: ...
full textMy Resources
Journal title
volume 2 issue 1
pages 32- 34
publication date 2010-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023